Here’s another collection of highly interesting stocks, laden with potential, from very different industries – but all currently under 50 cents in price.
Cancer is one of the most interesting areas of work of the ASX’s growing cohort of life sciences companies. Here are three of the fascinating stories emerging from this area.
Here are three stocks poised to smash through the $20 level in share price – in the cases of Orica and Northern Star, heading back above $20.
Here are two micro-cap companies that ply their trade in industries where both regulation and the search for economic efficiency is pushing participants toward the solutions they offer. Patient investors could be well-rewarded in the long run.
Here’s a look at four ASX companies that say they’re global leaders, and are hoping to be the next WiseTech, replicating what it has done in the global logistics industry.
Anecdotal evidence from many tourism operators points to Aussie travellers rethinking travel plans to travel at home – where the Australian dollar will always be an Australian dollar. Here are two potential exposures that analysts think represent good value.
There are pockets of value still to be mined in the sector. Here are two mid-tier gold producers that fit the bill very nicely.
The outlook for CSL (one of the few true global leaders on the ASX) from the analysts (who aren’t always right) is that the recent price decline gives investors an improved access point to a high-quality global healthcare exposure. Let’s put CSL under the microscope.
Beyond tariffs, I think there’s one part of the Trump Administration’s rhetoric that rewards a bit of exploration down in micro-cap world.
Here’s a look at three situations that look capable of producing good earnings growth this year – but there still looks to be value in the share price.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.